Literature DB >> 8408661

Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells.

K Yokokawa1, H Tahara, M Kohno, A K Mandal, M Yanagisawa, T Takeda.   

Abstract

Heparin shows blood pressure lowering effect in hypertensive patients and animal models. The present study examined the effect of heparin on vasoconstrictor endothelin-1 (ET-1) production in cultured human umbilical vein endothelial cells (ECs) to elucidate the mechanism of antihypertensive effect of heparin. Heparin suppressed both basal and thrombin-stimulated ET-1 mRNA expression paralleled with a decrease in ET-1 peptide release in a dose-dependent manner. Heparin concomitantly enhanced nitric oxide (NO) formation measured by NO2/NO3 levels and cGMP production in ECs. These enhancements were more marked when ECs were stimulated by thrombin. However, these heparin's effects were blunted in the presence of endothelium-derived nitric oxide (EDNO) synthesizing inhibitor NG-monomethyl L-arginine. Therefore, these results suggest that suppression of ET-1 production by heparin is EDNO mediated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8408661      PMCID: PMC288378          DOI: 10.1172/JCI116805

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Hypertension associated with endothelin-secreting malignant hemangioendothelioma.

Authors:  K Yokokawa; H Tahara; M Kohno; K Murakawa; K Yasunari; K Nakagawa; T Hamada; S Otani; M Yanagisawa; T Takeda
Journal:  Ann Intern Med       Date:  1991-02-01       Impact factor: 25.391

2.  Endothelin-secreting tumor.

Authors:  K Yokokawa; H Tahara; M Kohno; K Murakawa; K Yasunari; K Nakagawa; T Hamada; S Otani; M Yanagisawa; T Takeda
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

3.  Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction.

Authors:  T Miyauchi; M Yanagisawa; T Tomizawa; Y Sugishita; N Suzuki; M Fujino; R Ajisaka; K Goto; T Masaki
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

4.  Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man.

Authors:  P Vallance; J Collier; S Moncada
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

5.  Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages.

Authors:  D L Granger; J B Hibbs; J R Perfect; D T Durack
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

6.  The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling.

Authors:  M Yanagisawa; A Inoue; Y Takuwa; Y Mitsui; M Kobayashi; T Masaki
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

7.  Stimulation of cyclic GMP production in cultured endothelial cells of the pig by bradykinin, adenosine diphosphate, calcium ionophore A23187 and nitric oxide.

Authors:  C Boulanger; V B Schini; S Moncada; P M Vanhoutte
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

8.  Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.

Authors:  C Boulanger; T F Lüscher
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

9.  Plasma immunoreactive endothelin in essential hypertension.

Authors:  M Kohno; K Yasunari; K Murakawa; K Yokokawa; T Horio; T Fukui; T Takeda
Journal:  Am J Med       Date:  1990-06       Impact factor: 4.965

10.  Endothelin-3 regulates endothelin-1 production in cultured human endothelial cells.

Authors:  K Yokokawa; M Kohno; K Yasunari; K Murakawa; T Takeda
Journal:  Hypertension       Date:  1991-09       Impact factor: 10.190

View more
  11 in total

1.  Off-pump myocardial revascularization attenuates endothelin-1 expression in systemic, pulmonary, and coronary circulation.

Authors:  Daniel Unić; Davor Barić; Kristina Brkić; Mislav Planinc; Dubravka Jonjić; Igor Rudež; Željko Sutlić
Journal:  Wien Klin Wochenschr       Date:  2014-11-15       Impact factor: 1.704

2.  Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography.

Authors:  Z S Kyriakides; D T Kremastinos; E Bofilis; D Tousoulis; A Antoniadis; D J Webb
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

Review 3.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

4.  Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits.

Authors:  C R White; V Darley-Usmar; W R Berrington; M McAdams; J Z Gore; J A Thompson; D A Parks; M M Tarpey; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

5.  Endothelial cell expression of vasoconstrictors and growth factors is regulated by smooth muscle cell-derived carbon monoxide.

Authors:  T Morita; S Kourembanas
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

6.  Heparin reduces serum levels of endothelin-1 and hepatic ischemia reperfusion injury in rabbits.

Authors:  T Matsumoto; M Yamaguchi; H Kikuchi; H Nakano; T Midorikawa; K Kumada; M Takeda
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

7.  Immature endothelial cells initiate endothelin-mediated constriction of newborn arteries.

Authors:  Fumin Chang; Sheila Flavahan; Nicholas A Flavahan
Journal:  J Physiol       Date:  2016-06-16       Impact factor: 5.182

Review 8.  The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development.

Authors:  Essam Elsayed; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2003-02       Impact factor: 2.300

Review 9.  Endothelin and myocardial ischemia.

Authors:  D Hasdai; R Kornowski; A Battler
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

10.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.